Attenuated cognitive decline in community-dwelling older adults with higher plasma adropin concentrations

Geetika Aggarwal[1,2,3], John E. Morley[2], Bruno Vellas[4], Andrew D. Nguyen[1,2,3. †], Andrew A. Butler[1,3,†], for the MAPT/DSA Group.

1. Henry and Amelia Nasrallah Center for Neuroscience, Saint Louis University, St. Louis, MO, USA.
2. Division of Geriatric Medicine, Department of Internal Medicine, Saint Louis University School of Medicine, St. Louis, MO, USA.
3. Department of Pharmacology & Physiology, Saint Louis University School of Medicine, St. Louis, MO, USA.
4. Gérontopôle de Toulouse, Institut du Vieillissement, Centre Hospitalo-Universitaire de Toulouse, 37 allées Jules Guesdes, 31000, Toulouse, France.

† Equal contributions and corresponding authors, email Andrew.butler@health.slu.edu and andy.d.nguyen@health.slu.edu

ABSTRACT

Increasing adropin levels in old C57BL/6J mice improves learning and memory. Adropin expression is highly expressed in post-mortem human brain samples relative to other tissues and correlates with RNA and protein signatures linked to cognitive decline. Whether circulating adropin levels correlate with cognitive decline in humans of advanced age is not known. Here we report plasma adropin concentrations predict cognitive decline in participants of the Multidomain Alzheimer Preventive Trial (MAPT; ClinicalTrials.gov Identifier, NCT00672685; mean age 75.8y, SD=4.5y, 60.2% female, n-452). Cognitive ability was evaluated using a composite cognitive score (CCS) that assessed four domains: memory, language, executive function, and orientation. Relationships between plasma adropin concentrations and changes in CCS (ΔCCS) during the study were examined using cox binomial regression or grouping into tertiles ranked by adropin values and controlling for age, time between baseline and final visit, baseline CCS, education and medication. Increasing plasma adropin levels associated with reduced risk of cognitive decline (HR=0.873, 95% CI 0.780-0.977, P=0.018). Between adropin tertiles, ΔCCS was significantly different (estimated marginal mean$\pm$SE for the 1st, 2nd, and 3rd adropin tertiles, -0.299$\pm$0.057; -0.252$\pm$0.057; -0.107$\pm$0.058; n=151,152, and 149, respectively; P<0.05 between 1st and 3rd adropin tertile). Protection was observed in carriers of the APOE ε4 allele. Plasma $A\beta_{42/40}$ ratios were significantly higher ratio in the 3rd adropin tertile. Collectively, these results suggest protection from cognitive decline in community-dwelling older adults with high circulating adropin levels. Further studies are needed to determine the underlying causes of the relationship and whether increasing adropin levels can delay cognitive decline.

INTRODUCTION

Aging is the most significant risk factor for cognitive decline and a diagnosis of dementia, of which Alzheimer's disease (AD) is the most prevalent. Faced with the demographic trends leading to an aging population, there is an urgent need to identify novel treatments and signatures predicting risk of cognitive decline with aging.

Adropin is a small 76 amino acid peptide encoded by the Energy Homeostasis Associated (ENHO) gene (1). While originally described as a secreted peptide (1), further study suggests adropin$^{1-76}$ might also function as a membrane-bound protein (2). This conclusion is supported by data from AlphaFold's transmembrane protein structure database (3) and the HMMTOP algorithm (4). The protein is nevertheless observed in blood specimens and media of cultured cells, suggesting that as-yet unidentified mechanisms release some part of the adropin peptide into the interstitial space. The putative extracellular domain (adropin$^{34-76}$) contains a sequence sufficient to induce biological responses in cultured cells and rodent models that parallels that observed with transgenic changes in expression of the full-length protein (5, 6). This also indicates potential endocrine functions. Indeed, circulating adropin levels exhibit relationships with indices of metabolic homeostasis (5) and vascular function (7-10) that are consistent with the responses observed in cultured cells and animal models to administration of the exogenous peptide.

In the human body, adropin expression is highest in the central nervous system (2, 11, 12). Experiments using rodent models suggest that higher-than normal activity of adropin by pharmacological or genetic methods preserves cognitive ability in the context of aging, metabolic stress, or cerebral ischemia (11, 13-15). In post-mortem brain samples from people of advanced age, expression profiling indicate adropin expression correlates with neurological conditions affecting risk of poor cognitive ability (11). Adropin expression correlates positively with transcriptomic signatures of mitochondrial and synaptic functions (11). On the other hand, adropin expression also correlates positively with markers of Aβ accumulation and Tau pathology (11), which are hallmark neuropathological features of AD (16).

Whether circulating adropin concentration correlate with cognitive ability and risk of cognitive decline with aging has not been reported. This is a critical gap in knowledge, as blood biomarkers provide easily accessible indicators of neurophysiological processes, aging-related neuropathology, and responses to therapeutic interventions. If identified as a biomarker, measurement of circulating adropin levels could have added value in that modification through enhancement of adropin signaling using synthetic protein- or genetic-approaches could be possible (11, 14, 15).

To address this gap in knowledge, we investigated of the relationships between plasma adropin concentrations and cognitive decline in community dwelling older adults. As circulating adropin concentrations correlate with cardio-metabolic conditions associated with obesity and aging (5, 6), a secondary analysis focused on relationships with indices of metabolic and vascular functions.

METHODS

Study population

The study participants were from the randomized controlled trial MAPT (ClinicalTrials.gov [NCT00672685]). The original study examined 1679 dementia-free older adults aged ≥ 70 years recruited with any of the following criteria: expressing spontaneous memory complaint; having limitation in at least one instrumental activity of daily, and slow gait speed (<0.8 m/s). Participants were excluded if any of the following criteria was met: a mini-mental state exam (MMSE) score ≤ 24, a diagnosis of dementia, exhibiting difficulties in performing the basic activities of daily living, and already taking polyunsaturated fatty acid supplementation. The MAPT tested multidomain interventions (physical activity, nutritional counselling, and cognitive training) and omega-3 supplementation, combined or alone, against placebo among older adults and examined changes in cognitive functions over a 3-year period(17). Participants were observed for two additional years, without receiving any intervention. The MAPT was approved by the ethics committee in Toulouse (CPP SOOM II). Written consent forms were obtained from all participants. All research was performed in accordance with relevant guidelines/regulations.

Calculation of the Compositive Cognitive Score (CCS)

Data from study participants was collected over a total of 11 visits (V1-V11). Participants completed a comprehensive assessment of four domains: memory (free and total recall of the Free and Cued Selective Reminding Test [FCSRT]), language (the Category Naming Test), executive function (the DSST-WAISR) and orientation (ten MMSE orientation items)(18). The CCS was calculated using the average of the Z-score of each domain. Data collected at V1 was used to calculate the initial mean and SD values of each test. This study compared CCS in participants without dementia. For this group of 452 participants, 37 were diagnosed with dementia. Data from the visit during which these participants were diagnosed with dementia was excluded from the analysis.

The change in CCS over time (ΔCCS) was calculated using the final measurement collected. Variability in time between the initial and final visits was controlled for using a regression approach, with initial age and years between the initial and final visit included as covariates in the analysis. Data from two methods of comparing adropin values with ΔCCS are presented. Plasma used for the study came mostly from V3 (n=419), which was 1 year after V1, and V5 (n=33) which occurred 2 years after V1. We compared plasma adropin concentrations collected at V3/V5 with ΔCCS over the full duration of the study, and with ΔCCS calculated using CCS values at V3 and V5 as baseline.

Measurement of plasma variables

The methods used and a description of the results from the measurement of other plasma variables reported here have been previously described(17, 19-22). Plasma adropin concentrations were measured using an enzyme immunoassay kit from Phoenix Pharmaceuticals, Inc. (cat. no. EK-032-35) following the manufacturer's protocol. Assay sensitivity reported by the manufacturer is 0.3 ng/ml, with a linear range from 0.3 to 8.2 ng/ml. Pilot experiments determined a 1:5 dilution of serum produced values within the linear range. Values >8.2 ng/ml were described as "high" and arbitrarily assigned a value of 8.5 ng/ml (19 out of 452 samples). The assay was performed in duplicates; values with a CV of >20% were

discarded. Plate controls included ‘in-house’ human plasma and the controls provided by the assay manufacturer. The %CV for the plate controls were 11% and 14%, respectively.

Statistical analysis

The data were collated and managed in Microsoft Excel prior to being imported into SPSS vers. 28.0.1.0 (IBM) for analysis. The relationship between plasma adropin concentration and change in CCS was initially modelled using cox binomial regression, with baseline age at V1 used as time and status defined as a decline in CCS of -0.3 or greater. Covariates used for the analysis include the number of years between V1 and the final visit used to calculate ΔCCS, sex (categorical) and APOE status (categorical, APOE ε4 positive or negative) , BMI at V1, medications, and years of education. For comparing cognitive decline between participants with lower than normal or higher than normal adropin, groups were separated into adropin tertiles using the 33rd and 67th percentiles of ranked data. The 1st, 2nd, and 3rd tertile corresponded with participants with low, ‘normal’, or high levels. As plasma adropin concentrations were significantly different between sex; assignment to tertiles was therefore performed separately with sex.

For comparisons between adropin tertiles, data were tested for homogeneity of variance. Data with equal distributions around the mean, or which passed the test following transformation (Log_{10}), were analyzed using ANCOVA. The covariates used for each analysis are indicated; post hoc comparisons between groups used the Least Significance Difference (LSD) test. Data failing test for homogeneity of variance were compared using a nonparametric test (Quade Nonparametric Analysis of Covariance) with covariates applied as indicated. Adjusted data are presented as estimated marginal means and std. error.

A numerical score was used to control for education (1=no diploma or less than primary school certificate, 2=primary school certificate, 3=secondary education, 4=high school diploma, 5=university level). To control for medication, study participants received scores of 0 (not prescribed) or 1 for drugs targeting the nervous system (analgesics, anesthetics, anti-epileptics, psychoanaleptics, psycholeptics, anti-parkinson drugs), lipid lowering agents (statins, fibrates, bile acid sequestrants, cholesterol absorption inhibitors), diabetes drugs (alpha glucosidase

inhibitors, sulfonamides, thiazolidinediones, DPP-4 inhibitors, biguanides, insulin analogs), drugs targeting the cardiovascular system (ACE inhibitors, ARB blockers, anti-adrenergic drugs), drugs for blood disorders (antithrombotic and antianemic agents), corticosteroids, anti-inflammatory and antirheumatic drugs, and thyroid medications. The participants received possibles score between 0 (no medication) and 8.

RESULTS

High plasma adropin concentrations predict slower aging-related cognitive decline

A cross-sectional comparison of plasma adropin concentrations and baseline CCS at the time of visit indicated no correlation (V3, n=419; V5, n=33; ρ=0.046). Whether plasma adropin concentrations predict risk of decline first used cox regression. A decline in cognitive score of -0.3 or more in one calendar year has been reported to predict increased risk for a future dementia diagnosis (23). For this study, we therefore defined a decline in CCS of -0.3 or more during the 5 years of the MAPT study as a significant event. Simple modelling using cox binomial regression analysis definng an event as decline in the CCS of -0.3 or more with baseline age, years between visits used to calculate ΔCCS, and stratification by APOE ε4 genotype (either null or one or more copies) indicated declining risk with increasing plasma adropin concentrations (HR=0.898, 95% CI 0.808-0.998, P=0.045). Adding confounding variables to the model (BMI, sex category, normalized plasma $A\beta_{42/40}$ ratio, medications, education) did not markedly change the result (HR=0.873, 95% CI 0.780-0.977, P=0.018).

This potential relationship was further investigated by separating study participants into 3 groups ranked low to high by plasma adropin concentration. Baseline data for the adropin tertiles are shown in **Table 1**. Age, BMI, and CCS at baseline (V1), and the % testing positive for APOE ε4 variant were not significantly different between adropin tertile. However, significant effects of sex were observed for plasma adropin concentrations and CCS (females>males). Sex and adropin-tertile were therefore used as the independent variables for the first analysis.

Plotting ΔCCS as a function of age at V1 indicated a less severe cognitive decline in participants in the highest adropin tertile (3rd) appears to be attenuated compared to the 1st and 2nd adropin tertiles (**Fig. 1A-C**). Plotting the cumulative hazard rate for the adropin-tertiles controlling for APOE status, sex, BMI, normalized plasma $AB_{42/40}$ ratio, education, and medications indicated a delayed rise in risk with age for the 3rd tertile (**Fig. 1D**). A 2-way ANCOVA (groups: sex, adropin tertile) was used to compare ΔCCS that controlled for baseline CCS, age at baseline, and years between baseline and final measurement. There was a strong trend for a difference between adropin tertile ($F_{2,452}$=2.974, P=0.054), with no effect of sex. As predicted, ΔCCS was lowest in the tertile with higher adropin (estimated marginal mean±SE of ΔCCS for 1st, 2nd, and 3rd adropin tertiles, -0.299±0.058; -0.252±0.057; -0.108±0.058, n=150,152, and 150, respectively; P<0.05 between 1st and 3rd adropin tertiles). Controlling for education and medication did not change the outcome ($F_{2,446}$=2.931, P=0.054; estimated marginal mean±SE of ΔCCS for 1st, 2nd, and 3rd adropin tertiles, -0.298±0.059, -0.253±0.057, and -0.104±0.059, P<0.05 between 1st and 3rd adropin tertiles). Medication usage and education were similar between tertiles (**Table 3, 4**).

Similar results were observed when using V3/V5 CCS values as the baseline measurement. After controlling for baseline CCS, age at baseline, years between baseline and final measurement, education, and medical treatment, there was a significant difference between tertiles ($F_{2,413}$=2.999, P=0.051), no effect of sex, and similar differences between tertiles (-0.377±0.053; -0.330±0.053, -0.191±0.057, for 1st, 2nd, and 3rd adropin tertiles, n=141/145/127; P<0.05 between 1st and 3rd adropin tertiles).

Data for other variables that indicate conditions that potentially influence cognitive decline are available for the majority of the study participants (plasma NfL(20), plasma $A\beta_{42/40}$ ratio (20, 22), APOE genotype) (**Table 1, 2**). Values for one of these variables (plasma $A\beta_{42/40}$ ratio) differed significantly between adropin tertiles, while for NfL there was a significant interaction between sex and adropin tertile (**Table 2**). When controlling for these values, there was still a significant difference between adropin tertile ($F_{2,382}$=3.820, P=0.023) when using V1 as baseline (**Fig. 1E**). When using V3/V5 CCS values as the baseline measurement, there was also a significant difference between adropin tertiles ($F_{2,386}$=4.044, P=0.018) (**Fig. 1E**). For the covariates used in

the analysis, age, plasma $A\beta_{42/40}$ ratio, and years between V3/V5 and final visit has significant effects (all $P<0.05$). Sex had no significant effect.

The APOE ε4 allele is the strongest genetic risk factor identified for AD, and it affects cholesterol homeostasis and transport and axonal myelination (24, 25). A 2-way ANCOVA comparing the degree of protection between adropin tertiles for participants with at least one APOE ε4 allele (N=107) or no copies (N=275) and controlling for age, years between visits, plasma $A\beta_{42/40}$ ratio, NfL, education, and medication indicated comparable outcomes between APOE genotypes (**Fig. 1F, G**). The difference between adropin tertile was still significant using either V1 ($F_{2,382}=4.497$; $P=0.012$, **Fig. 1F**) or V3/V5 ($F_{2,356}=3.819$, $P=0.023$, **Fig. 1G**) as baseline in the calculation of ΔCCS. While there was no interaction between APOE ε4 genotype and adropin tertile, in the post-hoc analysis significant differences between adropin tertile were only observed in the APOE ε4 allele group (**Fig. 1F, G**). Higher than normal adropin levels thus still correlate with protection from cognitive decline irrespective of APOE genotype.

Plasma adropin concentrations correlate positively with $A\beta_{42/40}$ ratio

RNA-seq data indicate that ENHO expression correlates positively with Aβ protein levels in post-mortem brain samples from people of advanced age.(11) The $A\beta_{42/40}$ ratio predicts of risk of AD, with an inverse association between $A\beta_{42/40}$ ratios and cortical levels of Aβ.(26) In the current study, normalized $A\beta_{42/40}$ ratio data was available for 422 people. Plasma adropin concentrations correlated positively with the normalized $A\beta_{42/40}$ ratio ($\rho=0.101$, $P<0.05$, n=422). The normalized $A\beta_{42/40}$ ratio was also significantly different between adropin tertiles (effect of adropin tertile, $F_{2,422}=4.502$, $P=0.012$); the significantly higher ratios in the 3rd adropin tertile (**Table 2**) could be consistent with the protection from cognitive impairment. Removal of a single outlier (male in the 3rd adropin tertile with an $A\beta_{42/40}$ ratio of 0.3341, 12 SD from the mean) did not affect the correlation ($\rho=0.100$, $P<0.05$, n=421). However, there was now a strong trend for a difference between adropin tertiles ($F_{2,421}=2.709$, $P=0.068$); the mean and SD for the 3rd adropin tertile changed to 0.115±0.014 (both sexes, n=135) and 0.114±0.012 for males only (n=53).

Assessment of other systemic markers of inflammation and cellular stress indicated no consistent pattern between tertiles (**Supplemental Table S1**).

Cross-section correlation between adropin levels and cardiovascular disease risk factors

Circulating adropin levels correlate with vascular function.(7-10) Analysis of standing and prone heart rate and blood pressure recorded on the same visit used to collect the plasma samples used for adropin measurement suggested a relationship. Simple modelling indicated a positive correlation between heart rate measured in the standing (ρ=0.159, P<0.001, N=448) or prone positions (ρ=0.105, P<0.05, N=447). Between adropin tertiles, heart rate and diastolic blood pressure adjusted for age and BMI were significantly lower in the 1st adropin tertile relative to the 2nd and 3rd tertiles (**Table 3**). The differences reported in blood pressure on V3 and V5 between adropin tertiles was not reflected in differences in prescriptions of cardiovascular drugs between tertiles (**Table 3**).

Several studies have reported relationships between circulating adropin levels and indices of metabolic condition, such fasting markers of insulin resistance (insulin, glucose) and atherogenic lipids (non-HDL cholesterol, triglycerides).(5, 6) Cross-sectional comparisons of plasma adropin concentrations with plasma markers of metabolic condition in samples obtained at V3 and V5 indicated high adropin levels appear to associate with poor glycemic control and high cholesterol levels (**Table 4**). The number of participants exhibiting incident diabetes (glucose value>125 mg/dL) at the time of sample collection was twice as high compared to the 1st and 2nd adropin tertiles.

Plasma levels of total and HDL-cholesterol were also lower in the 1st adropin tertile relative to the 2nd and 3rd adropin tertiles. Plasma levels of ApoB100, which is also a strong predictor of risk for cardiovascular disease, were lowest in the 1st adropin tertile. However, there was no difference in drug prescriptions for cardiovascular conditions between tertile (**Table 3**). The differences in blood glucose and lipid reported on V3 and V5 between adropin tertiles was not reflected in differences in prescriptions of anit-diabetes or lipid-lowering drugs between tertiles (**Table 3**).

DISCUSSION

Increasing adropin activity in male C57BL/6J mice aged 18-20 months, corresponding to a human age of 56-69 years, improves cognitive ability as assessed by tests of spatial learning and memory.(11) Whether a relationship exists between adropin expression and cognitive ability in humans is not known. Data from The Aging, Dementia and TBI Study indicated relationships between expression of the ENHO transcript encoding adropin and transcriptomic and protein signatures of brain health that could be interpreted in two ways.(11) On the one hand, there was a positive correlation with transcriptomic signatures of mitochondrial function and synaptic plasticity. High adropin activity in the brain could therefore correlate positively with brain energy metabolism and neural activity. However, a positive association with protein markers of Aβ accumulation and Tau pathology in the brain were also noted. While the results from mouse studies suggest the relationship between adropin and cognitive health would be positive as opposed to negative, either outcome was considered possible for the current study.

The main outcomes from the current study suggest that people of advanced age with higher levels of adropin in the circulation are protected from cognitive decline. This interpretation is consistent with data from experiments using mouse models that demonstrated increasing adropin activity enhances cognitive ability.(11, 14, 15, 27) This finding is important for two reasons. First, it suggests an opportunity for developing an additional plasma biomarker indicating risk of cognitive decline. Secondly, results from preclinical experiments using mouse models indicate the people with lower-than-normal circulating adropin levels might benefit from therapies that increase adropin signaling. Knowledge of the source and sequences of the adropin peptides will be critical for the development of adropin analogs for use in clinical studies.

The positive relationship between plasma adropin levels and normalized plasma $A\beta_{42/40}$ ratio is an exciting observation, and consistent with high circulating adropin levels being a protective signal in the context of brain aging. Higher plasma $A\beta_{42/40}$ ratios are an indicator of reduced risk of amyloidosis, cognitive decline, or developing AD dementia.(26) The higher levels in participants in the 3rd adropin tertile is therefore consistent with delayed neurodegeneration

which could contribute to protection from cognitive decline. Clearly, further studies examining the relationship between circulating adropin levels and amyloidosis in the nervous system are warranted.

Another caveat to interpreting the results from this study is that the lack of information on the source of adropin peptide in the circulation. In mice, both protein and mRNA expression of adropin are high in the brain relative to other tissues.(1, 2) Expression of the mRNA encoding adropin is also far higher in the nervous system relative to other tissues in post-mortem samples from nonhuman primates and humans.(11, 12) Whether circulating adropin levels correlate with expression in the nervous system, or with levels in cerebrospinal fluid, is not known. Indeed, while one interpretation of this data is that circulating adropin levels correlate with activity in the nervous system, experiments using mouse models of ischemia indicate the blood-brain barriers as a critical target.(14, 27) The blood-brain barrier has a critical role in maintaining brain health and preventing dementia during aging.(28, 29) Further experiments are needed to determine whether circulating adropin levels correlate directly with activity of the peptide in the brain or indicate an indirect relationship reflecting functions of the blood brain barrier. Advances in our knowledge of the signaling mechanisms involved are also required. The only signaling pathway currently known to be necessary for adropin activity in the brain involves eNOS signaling.(27)

The current study also compared plasma adropin concentrations with indicators of cardiovascular and metabolic homeostasis. In a cross-sectional analysis of the data collected at V3 and V5, participants with high adropin appear to be more at risk for cardiovascular disease, indicated by higher levels of total cholesterol and ApoB100. High adropin also appears to correlate with a higher heart rate and diastolic blood pressure, which could indicate poor vascular condition. High adropin levels also appear to associate with elevated blood glucose and increased risk of incident diabetes. These results suggest that delay or prevention of cognitive decline is independent of improved cardiovascular health and metabolic control. Increased adropin expression and/or release into the circulation could be a protective-adaptive response to stress. Indeed, experiments in mice indicate that increased adropin expression in non-neural tissues is a component of a cellular-stress response.(30, 31) However, in the current

study there was no correlation with circulating markers of axonal damage, inflammation or cellular stress response. The relationship between circulating adropin and risk of cognitive decline thus appears to involve other pathways that will require further study to identify. Moreover, there was no difference in the prescription of medications against diabetes, dyslipidemia, or diabetes between adropin tertile. The relationship observed between plasma adropin and indices of glucose or lipid metabolism thus reflects the conditions on the day of measurement.

In conclusion, the results of this study indicate that high plasma adropin concentrations associate with attenuated cognitive decline in older people. Further studies exploring the relationships between circulating adropin and neurological aging, and the mechanisms that underly this association, are clearly warranted.

Contributors

AAB, ADN, BV, and JEM co-designed the study. GA, AAB, and ADN collected the data. GA verified the underlying data. AAB analyzed the data and prepared the first draft of the manuscript. All authors contributed to the interpretation of the results and critically reviewed the manuscript. All authors read and approved the final version of the manuscript.

Data sharing statement

A de-identified data set can be made available to academic researchers who provide a methodologically sound proposal that is approved by the MAPT/DSA group. Enquiries should be directed to: nicola.coley@inserm.fr.

Disclosures

None declared.

Acknowledgments

AAB and ADN acknowledge financial support provided by Saint Louis University. The authors thank Prof. Randall J. Bateman (Department of Neurology, Washington University School

of Medicine, 660 South Euclid Avenue, Box 8111, St. Louis, MO 63110 USA) for measurement of plasma $A\beta_{42/40}$ ratio. The authors also thanks Dr. Theodore Malmstrom (Department of Psychiatry & Behavioiral Neuroscience, Saint Louis University School of Medicine, 1438 South Grand Boulevard, St. Louis, MO 63104 USA) for discussion on statistical analysis. The MAPT study was supported by grants from the Gérontopôle of Toulouse, the French Ministry of Health (PHRC 2008, 2009), Pierre Fabre Research Institute (manufacturer of the omega-3 supplement), ExonHit Therapeutics SA, and Avid Radiopharmaceuticals Inc. The promotion of this study was supported by the University Hospital Center of Toulouse. The data sharing activity was supported by the Association Monegasque pour la Recherche sur la maladie d'Alzheimer (AMPA) and the INSERM-University of Toulouse III UMR 1295 (CERPOP) Research Unit

References

1. Kumar KG, Trevaskis JL, Lam DD, Sutton GM, Koza RA, Chouljenko VN, et al. Identification of adropin as a secreted factor linking dietary macronutrient intake with energy homeostasis and lipid metabolism. Cell Metab. 2008;8(6):468-81.

2. Wong CM, Wang Y, Lee JT, Huang Z, Wu D, Xu A, et al. Adropin is a brain membrane-bound protein regulating physical activity via the NB-3/Notch signaling pathway in mice. J Biol Chem. 2014;289(37):25976-86.

3. Jumper J, Evans R, Pritzel A, Green T, Figurnov M, Ronneberger O, et al. Highly accurate protein structure prediction with AlphaFold. Nature. 2021;596(7873):583-9.

4. Tusnady GE, Simon I. The HMMTOP transmembrane topology prediction server. Bioinformatics. 2001;17(9):849-50.

5. Butler AA, Havel PJ. Adropin and insulin resistance: Integration of endocrine, circadian, and stress signals regulating glucose metabolism. Obesity (Silver Spring). 2021;29(11):1799-801.

6. Mushala BAS, Scott I. Adropin: a hepatokine modulator of vascular function and cardiac fuel metabolism. Am J Physiol Heart Circ Physiol. 2021;320(1):H238-H44.

7. Jurrissen TJ, Ramirez-Perez FI, Cabral-Amador FJ, Soares RN, Pettit-Mee RJ, Betancourt-Cortes EE, et al. Role of adropin in arterial stiffening associated with obesity and type 2 diabetes. Am J Physiol Heart Circ Physiol. 2022;323(5):H879-H91.

8. Fujie S, Hasegawa N, Horii N, Uchida M, Sanada K, Hamaoka T, et al. Aerobic Exercise Restores Aging-Associated Reductions in Arterial Adropin Levels and Improves Adropin-Induced Nitric Oxide-Dependent Vasorelaxation. J Am Heart Assoc. 2021:e020641.

9. Fujie S, Hasegawa N, Kurihara T, Sanada K, Hamaoka T, Iemitsu M. Association between aerobic exercise training effects of serum adropin level, arterial stiffness, and adiposity in obese elderly adults. Appl Physiol Nutr Metab. 2017;42(1):8-14.

10. Fujie S, Hasegawa N, Sato K, Fujita S, Sanada K, Hamaoka T, et al. Aerobic exercise training-induced changes in serum adropin level are associated with reduced arterial stiffness in middle-aged and older adults. Am J Physiol Heart Circ Physiol. 2015;309(10):H1642-7.

11. Banerjee S, Ghoshal S, Girardet C, DeMars KM, Yang C, Niehoff ML, et al. Adropin correlates with aging-related neuropathology in humans and improves cognitive function in aging mice. NPJ Aging Mech Dis. 2021;7(1):23.

12. Butler AA, Zhang J, Price CA, Stevens JR, Graham JL, Stanhope KL, et al. Low plasma adropin concentrations increase risks of weight gain and metabolic dysregulation in response to a high-sugar diet in male nonhuman primates. J Biol Chem. 2019;294(25):9706-19.

13. Yang C, DeMars KM, Candelario-Jalil E. Age-Dependent Decrease in Adropin is Associated with Reduced Levels of Endothelial Nitric Oxide Synthase and Increased Oxidative Stress in the Rat Brain. Aging Dis. 2018;9(2):322-30.

14. Yang C, Liu L, Lavayen BP, Larochelle J, Gunraj RE, Butler AA, et al. Therapeutic Benefits of Adropin in Aged Mice After Transient Ischemic Stroke via Reduction of Blood-Brain Barrier Damage. Stroke. 2023;54(1):234-44.

15. Ghoshal S, Banerjee S, Zhang J, Niehoff ML, Farr SA, Butler AA. Adropin transgenesis improves recognition memory in diet-induced obese LDLR-deficient C57BL/6J mice. Peptides. 2021;146:170678.

16. Jack CR, Jr., Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, et al. NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease. Alzheimers Dement. 2018;14(4):535-62.

17. Vellas B, Carrie I, Gillette-Guyonnet S, Touchon J, Dantoine T, Dartigues JF, et al. Mapt Study: A Multidomain Approach for Preventing Alzheimer's Disease: Design and Baseline Data. J Prev Alzheimers Dis. 2014;1(1):13-22.

18. Andrieu S, Guyonnet S, Coley N, Cantet C, Bonnefoy M, Bordes S, et al. Effect of long-term omega 3 polyunsaturated fatty acid supplementation with or without multidomain intervention on cognitive function in elderly adults with memory complaints (MAPT): a randomised, placebo-controlled trial. Lancet Neurol. 2017;16(5):377-89.

19. Giudici KV, Barreto PS, Guyonnet S, Morley JE, Nguyen AD, Aggarwal G, et al. TNFR-1 and GDF-15 are associated with plasma neurofilament light chain and progranulin among community-dwelling older adults: a secondary analysis of the MAPT Study. J Gerontol A Biol Sci Med Sci. 2022.

20. He L, de Souto Barreto P, Aggarwal G, Nguyen AD, Morley JE, Li Y, et al. Plasma Abeta and neurofilament light chain are associated with cognitive and physical function decline in non-dementia older adults. Alzheimers Res Ther. 2020;12(1):128.

21. Lu WH, Giudici KV, Rolland Y, Guyonnet S, Li Y, Bateman RJ, et al. Prospective Associations between Plasma Amyloid-Beta 42/40 and Frailty in Community-Dwelling Older Adults. J Prev Alzheimers Dis. 2021;8(1):41-7.

22. Giudici KV, de Souto Barreto P, Guyonnet S, Li Y, Bateman RJ, Vellas B, et al. Assessment of Plasma Amyloid-beta42/40 and Cognitive Decline Among Community-Dwelling Older Adults. JAMA Netw Open. 2020;3(12):e2028634.

23. Coley N, Gallini A, Ousset PJ, Vellas B, Andrieu S, GuidAge study g. Evaluating the clinical relevance of a cognitive composite outcome measure: An analysis of 1414 participants from the 5-year GuidAge Alzheimer's prevention trial. Alzheimers Dement. 2016;12(12):1216-25.

24. Carlstrom K, Castelo-Branco G. Alzheimer's risk variant APOE4 linked to myelin-assembly malfunction. Nature. 2022;611(7937):670-1.

25. Dolgin E. This is how an Alzheimer's gene ravages the brain. Nature. 2022;611(7937):649.

26. Brand AL, Lawler PE, Bollinger JG, Li Y, Schindler SE, Li M, et al. The performance of plasma amyloid beta measurements in identifying amyloid plaques in Alzheimer's disease: a literature review. Alzheimers Res Ther. 2022;14(1):195.

27. Yang C, Lavayen BP, Liu L, Sanz BD, DeMars KM, Larochelle J, et al. Neurovascular protection by adropin in experimental ischemic stroke through an endothelial nitric oxide synthase-dependent mechanism. Redox Biol. 2021;48:102197.

28. Banks WA, Reed MJ, Logsdon AF, Rhea EM, Erickson MA. Healthy aging and the blood-brain barrier. Nat Aging. 2021;1(3):243-54.

29. Segarra M, Aburto MR, Acker-Palmer A. Blood-Brain Barrier Dynamics to Maintain Brain Homeostasis. Trends Neurosci. 2021;44(5):393-405.

30. Banerjee S, Ghoshal S, Stevens JR, McCommis KS, Gao S, Castro-Sepulveda M, et al. Hepatocyte expression of the micropeptide adropin regulates the liver fasting response and is enhanced by caloric restriction. J Biol Chem. 2020;295(40):13753-68.

31. Chen X, Xue H, Fang W, Chen K, Chen S, Yang W, et al. Adropin protects against liver injury in nonalcoholic steatohepatitis via the Nrf2 mediated antioxidant capacity. Redox Biol. 2019;21:101068.

Collaborators (members of the MAPTDSA group):

Principal investigator: Bruno Vellas (Toulouse); Coordination: Sophie Guyonnet ; Project leader: Isabelle Carrié ; CRA: Lauréane Brigitte ; Investigators: Catherine Faisant, Françoise Lala, Julien Delrieu, Hélène Villars ; Psychologists: Emeline Combrouze, Carole Badufle, Audrey Zueras ; Methodology, statistical analysis and data management: Sandrine Andrieu, Christelle Cantet, Christophe Morin; Multidomain group: Gabor Abellan Van Kan, Charlotte Dupuy, Yves Rolland (physical and nutritional components), Céline Caillaud, Pierre-Jean Ousset (cognitive component), Françoise Lala (preventive consultation). The cognitive component was designed in collaboration with Sherry Willis from the University of Seattle, and Sylvie Belleville, Brigitte Gilbert and Francine Fontaine from the University of Montreal. Co-Investigators in associated centres: Jean-François Dartigues, Isabelle Marcet, Fleur Delva, Alexandra Foubert, Sandrine Cerda (Bordeaux); Marie-Noëlle-Cuffi, Corinne Costes (Castres); Olivier Rouaud, Patrick Manckoundia, Valérie Quipourt, Sophie Marilier, Evelyne Franon (Dijon); Lawrence Bories, Marie-Laure Pader, Marie-France Basset, Bruno Lapoujade, Valérie Faure, Michael Li Yung Tong, Christine Malick-Loiseau, Evelyne Cazaban-Campistron (Foix); Françoise Desclaux, Colette Blatge (Lavaur); Thierry Dantoine, Cécile Laubarie-Mouret, Isabelle Saulnier, Jean-Pierre Clément, Marie-Agnès Picat, Laurence Bernard-Bourzeix, Stéphanie Willebois, Iléana Désormais, Noëlle Cardinaud (Limoges); Marc Bonnefoy, Pierre Livet, Pascale Rebaudet, Claire Gédéon, Catherine Burdet, Flavien Terracol (Lyon), Alain Pesce, Stéphanie Roth, Sylvie Chaillou, Sandrine Louchart (Monaco); Kristel Sudres, Nicolas Lebrun, Nadège Barro-Belaygues (Montauban); Jacques Touchon, Karim Bennys, Audrey Gabelle, Aurélia Romano, Lynda Touati, Cécilia Marelli, Cécile Pays (Montpellier); Philippe Robert, Franck Le Duff, Claire Gervais, Sébastien Gonfrier (Nice); Yannick Gasnier and Serge Bordes, Danièle Begorre, Christian Carpuat, Khaled Khales, Jean-François Lefebvre, Samira Misbah El Idrissi, Pierre Skolil, Jean-Pierre Salles (Tarbes). MRI group: Carole Dufouil (Bordeaux), Stéphane Lehéricy, Marie Chupin, Jean-François Mangin, Ali Bouhayia (Paris); Michèle Allard (Bordeaux); Frédéric Ricolfi (Dijon); Dominique Dubois (Foix); Marie Paule Bonceour Martel (Limoges); François Cotton (Lyon); Alain Bonafé (Montpellier); Stéphane Chanalet (Nice); Françoise Hugon (Tarbes); Fabrice Bonneville, Christophe Cognard, François Chollet (Toulouse). PET scans group: Pierre Payoux, Thierry Voisin, Julien Delrieu, Sophie Peiffer, Anne Hitzel, (Toulouse); Michèle Allard (Bordeaux); Michel Zanca (Montpellier); Jacques Monteil (Limoges); Jacques Darcourt (Nice). Medico-economics group: Laurent Molinier, Hélène Derumeaux, Nadège Costa (Toulouse). Biological sample collection: Bertrand Perret, Claire Vinel, Sylvie Caspar-Bauguil (Toulouse).
Safety management: Pascale Olivier-Abbal. DSA Group: Sandrine Andrieu, Christelle Cantet, Nicola Coley

Table 1. Baseline (V1) data for subjects grouped into adropin tertiles. Plasma adropin concentrations and age are shown as mean and SD of the actual values. CCS at baseline are estimated marginal means and SE of values adjusted for age, medication, and years of education for measurements on the same visit as plasma sample collection (V3, V5). Body mass index (BMI) is shown as estimated marginal mean adjusted for age. Sample sizes are indicated in brackets. P values for covariates less than 0.05 are shown in *italics*.

Metric	Sex	Adropin tertile				P value
		(ALL)	1st	2nd	3rd	
Plasma Adropin (ng/ml)	F	4.21±1.70 (272)	2.43±0.77 (90)	4.12±0.39 (91)	6.06±1.16 (91)	Sex P<0.01
	M	3.73±1.80 (180)	2.05±0.47 (60)	3.38±0.38 (61)	5.80± 1.51 (59)	
	ALL	4.02±1.76 (452)	2.34±1.01 (150)	3.83±0.53 (152)	5.94±1.40 (150)	Tertile P<0.01
CCS	F	+0.180±0.042 (265)	+0.195±0.072 (88)	+0.206±0.071 (91)	+0.139±0.073 (86)	*Education, Age P<0.001*
	M	-0.055±0.051 (174)	-0.015±0.090 (56)	-0.130±0.087 (61)	-0.021±0.091 (57)	
	ALL	0.062±0.033 (439)	0.090±0.057 (144)	0.038±0.056 (152)	0.059±0.058 (143)	Sex P<0.01
Age, V1 (yr)	F	75.6±4.4 (272)	76.2±4.7 (90)	75.0±4.2 (91)	75.8±4.3 (91)	
	M	76.0±4.7 (180)	75.5±4.5 (60)	75.9±4.6 (61)	76.8±5.0 (59)	
	ALL	75.8±4.5 (452)	75.9±4.6 (150)	75.3±4.3 (152)	76.2±4.6 (150)	
BMI (kg/m^2)	F	25.8±0.2 (271)	25.7±0.4 (89)	26.3±0.4 (91)	25.5±0.4 (91)	
	M	26.7±0.3 (179)	27.0±0.5 (60)	26.8±0.5 (60)	26.3±0.5 (59)	
	ALL	26.3±0.2 (450)	26.4±0.3 (149)	26.6±0.3 (151)	25.9±0.3 (150)	
APOE ε4 (%ve with at least one copy)	F	28% (248)	33% (82)	24% (86)	26% (80)	
	M	27% (166)	27% (55)	33% (60)	20% (51)	
	ALL	28% (414)	31% (137)	28% (146)	24% (141)	

Table 2. Plasma concentrations of markers of neurodegeneration (NfL, $AB_{42/40}$). Plasma normalized $A\beta_{42/40}$ ratio is presented as estimated marginal mean and SE adjusted for age. NfL values are adjusted for age. P values for covariates less than 0.05 are shown in *italics*.

Metric	Sex	Adropin tertile				P value
		(ALL)	1st	2nd	3rd	
$A\beta_{42/40}$ (ratio)	F	0.115±0.001 (251)	0.114±0.002 (83)	0.114±0.002 (85)	0.116±0.002 (83)	*Education,* P<0.05
	M	0.112±0.001 (171)	0.110±0.001 (56)	0.109±0.002 (61)	0.118±0.002[1] (54)	Tertile P<0.05
	ALL	0.114±0.001 (422)	0.112±0.002 (139)	0.111±0.002 (146)	0.117±0.002[1] (137)	
NfL (pg/mL)	F	85.8±4.5 (248)	80.0±7.7 (71)	97.4±7.7 (87)	79.9±7.7 (90)	*Age, P=0.005*
	M	87.9±5.5 (171)	101.3±9.5[2] (53)	84.4±9.4 (59)	78.1±9.6 (59)	Sex X Adropin tertile, P<0.05
	ALL	86.9±3.5 (419)	90.7±6.1 (124)	90.9±6.1 (146)	79.0±6.2 (149)	

[1] P<0.05 vs. 1st adropin tertile; P<0.01 vs. 2nd adropin tertile (within rows); [2] P<0.05 vs. 3rd adropin tertile, P<0.01 vs. 2nd adropin tertile.

Table 3. Indices of cardiovascular function. Data shown are estimated marginal means and SE adjusted for age and BMI. The % taking medications for cardiovascular conditions (antihypertensives) during the first 3 years of the study P values for covariates less than 0.05 are shown in *italics*.

Metric	Sex	Adropin tertile				P value
		(ALL)	1st	2nd	3rd	
Pulse rate (standing)	F	75.4±0.7 (269)	73.7±1.2[2] (89)	75.0±1.2 (91)	77.5±1.2[1,2] (89)	*BMI, P<0.05*
	M	71.4±0.9 (178)	69.1±1.5 (59)	74.9±1.5[1] (60)	70.1±1.5 (59)	Sex, P<0.001 Tertile, P<0.05
	ALL	73.4±0.5 (447)	71.4±1.0 (148)	75.0±0.9[1] (151)	73.8±1.0 (148)	Sex X tertile, P<0.05
Pulse rate (prone)	F	70.3±0.6 (270)	67.6±1.1 (89)	70.6±1.1 (91)	72.8±1.1[4,5] (90)	*BMI, P<0.05*
	M	67.5±0.8 (178)	64.3±1.4 (59)	70.9±1.3[5] (60)	67.2±1.4 (59)	Sex, P=0.005 Tertile,P<0.001
	ALL	68.9±0.5 (448)	65.9±0.9[3] (148)	70.7±0.9 (151)	70.0±0.9 (149)	Sex X Tertile. P=0.052
Systolic blood pressure (standing)	F	134.6±1.2 (269)	131.2±2.2 (89)	136.7±2.1 (91)	135.9±2.2 (89)	*Age, P=0.001*
	M	137.4±1.5 (178)	138.4±2.7 (59)	136.5±2.6 (60)	137.4±2.7 (59)	*BMI P=0.001*
	ALL	136.0±1.0 (447)	134.8±1.7 (148)	136.6±1.7 (151)	136.6±1.7 (148)	
Systolic blood pressure (Prone)	F	137.0±1.1 (270)	134.4±2.0 (89)	138.5±2.0 (91)	137.9±2.0 (90)	*Age, P=0.003*
	M	139.1±1.4 (178)	142.1±2.4 (59)	138.7±2.4 (60)	136.7±2.4 (59)	*BMI P=0.002*
	ALL	138.0±0.9 (448)	138.3±1.6 (148)	138.6±1.6 (151)	137.3±1.6 (149)	
Diastolic blood pressure (standing)	F	78.7±0.8 (269)	75.9±1.3 (89)	79.2±1.3 (91)	81.2±1.3[6] (89)	*BMI, P<0.001*
	M	79.5±0.9 (178)	79.2±1.6 (59)	81.5±1.6 (60)	77.8±1.6 (59)	Sex X tertile
	ALL	79.1±0.6 (447)	77.5±1.1 (148)	80.4±1.0[1] (151)	79.5±1.1 (148)	P=0.055

Diastolic blood pressure (prone)	F M ALL	77.4±0.7 (270) 78.0±0.9 (178) 77.7±0.6 (448)	76.1±1.3 (89) 79.8±1.6 (59) 77.9±1.0 (148)	76.9±1.3 (91) 78.1±1.6 (60) 77.5±1.0 (151)	79.2±1.6 (90) 76.1±1.6 (59) 77.7±1.0 (149)	*BMI, P<0.001* Sex X tertile P=0.056
Cardiovascular medications (% prescribed)	ALL	44.9%	42.0%	48.7%	44.0%	

[1] P<0.05 vs. 1st adropin tertile within row (All), P<0.01 vs. 1st adropin tertile and <0.05 vs. 3rd adropin tertle within row (males) ; [2] P<0.001 (3rd tertile) or <0.05 (1st tertile) between sexes (within column);[3] P<0.001 vs. 2nd, 3rd adropin tertiles (within row); [4] P=0.001 between sexes (within column);[5] P<0.001 vs. 1st adropin tertile (within row), and [6] P=0.005 vs. 1st adropin tertile (within row)

Table 4. Cross-sectional analysis of indices of glucose and lipid homeostasis (age, BMI adjusted) between adropin tertile. The values shown were measured during the same visit (V3, V5); the percent reporting medications during the first 3 years of the study for treating diabetes and dyslipidemia are shown. P values for covariates less than 0.05 are shown in *italics*.

Metric	Sex	Adropin tertile				P value
		(ALL)	1st	2nd	3rd	
Glucose (mg/dL)	F	99.3±2.2 (249)	96.0±3.8 (80)	98.1±3.6 (89)	103.7±3.8 (80)	
	M	104.1±2.6 (165)	100.2±4.5 (58)	95.8±4.6 (54)	116.4±4.7 (53)	
	ALL	101.7±1.7 (414)	98.1±2.9 (138)	97.0±2.9 (143)	110.0±3.0 (133)	
Incident diabetes (% >125 mg/dL)	F	9.6% (24/227)	7.4% (7/76)	7.9% (7/82)	13.6% (11/69)	
	M	14.6% (24/142)	13.8% (8/50)	7.3% (4/51)	22.6% (12/41)	
	ALL	12.1% (48/417)	10.6% (14/125)	7.6% (11/133)	18.1% (23/111)	$\chi^2_{(2,417)}$ =6.607, P<0.05 (ALL)
Anti-diabetic medication	ALL	10.8%	12.0%	6.6%	14.0%	
Cholesterol (mg/dL)	F	226.8±2.6 (250)	224.8±4.5 (81)	230.4±4.3 (90)	225.2±4.6 (79)	*Age, P<0.05*
	M	205.7±3.2 (164)	192.5±5.3[1] (58)	212.3±5.5 (54)	212.4±5.6 (52)	Sex, P<0.001
	ALL	216.3±2.0 (414)	208.7±3.5[2] (138)	221.4±3.5 (144)	218.8±3.6 (132)	Tertile, P<0.05
HDL-cholesterol (mg/dL)	F	70.2±0.9 (249)	64.8±1.7[3] (80)	72.1±1.6 (90)	73.9±1.7 (79)	*BMI, P<0.001*
	M	58.7±1.2 (164)	57.2±2.0 (58)	58.5±2.0 (54)	60.4±2.1 (52)	Sex, P<0.001
	ALL	64.5±0.7 (413)	61.0±1.3[4] (138)	65.3±1.3 (144)	67.1±1.3 (13`)	Tertile, P<0.005

ApoA1 (mg/dL)	F	135.4±2.1 (240)	130.7±3.9 (67)	137.7±3.5 (85)	137.7±3.4 (88)	*BMI, P<0.001*
	M	122.7±2.5 (167)	116.9±4.4 (53)	127.6±4.2 (56)	123.5±4.2 (58)	Sex, P<0.001
	ALL	129.0±1.6 (407)	123.8±2.9 (120)	132.6±2.7 (139)	130.6±2.7 (140)	
ApoB100 (mg/dL)	F	87.3±1.8 (240)	85.0±3.4 (67)	88.7±3.0 (85)	88.1±3.0 (88)	Tertile, P<0.001
	M	83.9±2.1 (167)	71.7±3.8[5] (53)	94.4±3.7 (56)	85.4±3.6 (58)	Sex X tertile, P<0.05
	ALL	85.6±1.4 (407)	78.4±2.5[6] (120)	91.6±2.4 (141)	86.8±2.4 (146)	
Triglycerides (mg/dL)	F	142.0±4.3 (250)	154.9±7.6 (80)	141.6±7.2 (90)	129.5±7.6 (80)	*BMI, P<0.001*
	M	145.4±5.3 (164)	137.7±8.9 (58)	152.0±9.2 (54)	146.6±9.4 (52)	
	ALL	143.7±3.4 (414)	146.3±5.8 (138)	146.8±5.8 (144)	138.1±6.0 (132)	
Lipid-lowering medication	ALL	44.2%	49.3%	44.7%	38.7%	

[1] P<0.5 vs. 2nd, 3rd adropin tertile;[2] P<0.05 vs. 2nd adropin tertile; [3] P<0.005 vs. 2nd, 3rd adropin tertile;[4] P<0.05 vs. 2nd adropin tertile, P<0.005 vs. 3rd adropin tertile;[6] P<0.001 vs. 2nd adropin tertile, P<0.05 vs. 3rd adropin tertile, and [6] P<0.05 vs. 2nd, 3rd adropin tertile

Supplemental Table 1. Plasma concentrations of markers of inflammation (soluble tumor necrosis factor receptor, sTNFR-1; monocyte chemoattractant protein 1, MCP-1; interleukin 6, IL-6, C-reactive protein, CRP) and cellular stress (plasma growth differentiation factor 15, GDF-15). The data shown were measured at V3 and V5, and are presented as estimated marginal means±SE adjusted for age. P values for covariates less than 0.05 are shown in *italics*.

Metric	Sex	Adropin tertile				P value
		(ALL)	1st	2nd	3rd	
sTNFR-1 (pg/mL)	F	1334±31 (240)	1283±57 (68)	1374±52 (84)	1345±50 (88)	*Age, P<0.001*
	M	1447±36 (167)	1493±65 (52)	1428±62 (57)	1418±62 (58)	Sex, P<0.05
	ALL	1390±24 (407)	1388±43 (120)	1401±40 (141)	1382±40 (146)	
MCP-1 (pg/mL)	F	248±6 (240)	244±11 (64)	236±10 (84)	265±10 (88)	
	M	242±7 (167)	235±13 (52)	229±12 (57)	262±12 (58)	
	ALL	245±5 (407)	239±9 (120)	233±8 (141)	263±8 (146)	
IL-6 (pg/mL)	F	5.65±1.19 (240)	9.36±2.23 (68)	4.02±2.01 (84)	3.57±1.96 (88)	
	M	3.97±1.42 (167)	3.90±2.55 (52)	3.69±2.43 (57)	4.31±2.42 (58)	
	ALL	4.81±0.93 (407)	6.63±1.69 (120)	3.86±1.58 (141)	3.94±1.56 (146)	
CRP (mg/L)	F	3.07±0.32 (245)	2.75±0.55 (80)	3.50±0.53 (87)	2.96±0.56 (78)	
	M	2.93±0.39 (163)	2.30±0.66 (56)	2.87±0.67 (55)	3.62±0.69 (52)	
	ALL	3.00±0.25 (408)	2.52±0.43 (136)	3.18±0.43 (142)	3.29±0.44 (130)	

GDF-15 (pg/mL)	F	1198±32 (239)	1225±59 (68)	1183±54 (83)	1184±52 (88)	*Age, P<0.001*
	M	1438±38 (167)	1571±68 (52)	1382±64 (57)	1361±64 (58)	Sex, P<0.001
	ALL	1318±25 (406)	1398±45 (120)	1283±42 (140)	1273±41 (146)	

Figure 1 (next page). Differences in cognitive decline between study participants grouped by adropin tertile. The scatterplots in **A-C** show the changes in composite cognitive score (ΔCCS) over a 1-4yr period as a function of age on the first visit (V1). The participants are divided into three groups (adropin tertiles) ranked low (1st) to high (3rd) For the 1st, 2nd, and 3rd adropin tertile, n=151, 152, and 149, respectively. (**D**) The increase in cumulative hazard with age for participants to exhibit a ΔCCS of -0.3 or more is delayed in the 3rd adropin tertile. (**E**) ΔCCS for the 1st-3rd adropin tertiles adjusted for age, sex, years between baseline and final measurement, NfL, $A\beta_{42/40}$ ratio(20, 22), and APOE ε4 status. For the data using V1 as baseline, n=127,140, and 119, respectively; for data using V3/V5 as baseline, n=124,133, and 104, respectively. (**F, G**). Comparing the effect of adropin tertile on ΔCCS between participants identified by APOE status (ε4 negative or positive; n=300 or 114, respectively). The data shown are estimated marginal means and SEM adjusted for age, sex, years between baseline and final measurement. For data using V1 as baseline, n=137, 146, and 131 (ε4 negative or positive); n=95, 105, 100 (ε4 negative or), or n=42,41, and 31 (ε4 positive). For data using V3/5 as baseline, n=134, 139, and 113 (ε4 negative or positive); n=93, 99, or 87 (ε4 negative or), or n=41,40, and 26 (ε4 positive). Significantly different from the 3rd adropin tertile, * $P<0.05$, ** $P<0.01$, *** $P\leqq0.005$.


1st adropin tertile
2nd adropin tertile
3rd adropin tertile
A
B
C
Δ CCS
Both sexes
Females
Males
Age @ V1
D
Cumulate Hazard
Adropin tertile
Age (baseline, yr)
E
Δ CCS
V1
V3/V5
Visit used for baseline calculation
(ALL)
Apoe ε4 –ve
Apoe ε4 +ve
(either)
F
V1 used for baseline
Δ CCS
Apoe ε4 (–ve)
Apoe ε4 (+ve)
G
V3/V5 used for baseline
Δ CCS
Apoe ε4 (–ve)
Apoe ε4 (+ve)